Multivariate analysis of transplant outcomes according to prednisone-equivalent dose of glucocorticoids for initial treatment of acute GVHD
| . | 1 mg/kg per day versus 2 mg/kg per day . | |||||
|---|---|---|---|---|---|---|
| All patients . | Grades IIb-IV . | Grades I-IIa . | ||||
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Nonrelapse mortality | 1.06 (0.8-1.5) | .73 | 1.48 (0.9-2.3) | .09 | 0.82 (0.5-1.3) | .37 |
| Relapse | 1.22 (0.9-1.7) | .26 | 0.85 (0.5-1.6) | .60 | 1.54 (1.0-2.4) | .05 |
| Overall mortality | 1.10 (0.9-1.4) | .42 | 1.15 (0.8-1.7) | .46 | 1.07 (0.8-1.5) | .70 |
| Chronic GVHD | 0.95 (0.8-1.2) | .61 | 0.97 (0.7-1.4) | .88 | 0.95 (0.7-1.2) | .65 |
| . | 1 mg/kg per day versus 2 mg/kg per day . | |||||
|---|---|---|---|---|---|---|
| All patients . | Grades IIb-IV . | Grades I-IIa . | ||||
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Nonrelapse mortality | 1.06 (0.8-1.5) | .73 | 1.48 (0.9-2.3) | .09 | 0.82 (0.5-1.3) | .37 |
| Relapse | 1.22 (0.9-1.7) | .26 | 0.85 (0.5-1.6) | .60 | 1.54 (1.0-2.4) | .05 |
| Overall mortality | 1.10 (0.9-1.4) | .42 | 1.15 (0.8-1.7) | .46 | 1.07 (0.8-1.5) | .70 |
| Chronic GVHD | 0.95 (0.8-1.2) | .61 | 0.97 (0.7-1.4) | .88 | 0.95 (0.7-1.2) | .65 |
Adjusted for GVHD grade at onset of treatment (I vs IIa vs IIb vs ≥ III), gut GVHD at onset (any vs none), patient age (continuous variable), donor type (unrelated vs other), donor/recipient HLA mismatch (any vs other) and sex mismatch (female donor with male recipient vs other), conditioning intensity (myeloablative vs nonmyeloablative), use of tacrolimus as part of the GVHD prophylaxis, year of transplantation (continuous variable), concurrent use of BDP and systemic glucocorticoids, and transplantation-to-treatment interval (continuous variable).